Sign in
4

Changes in Ownership

Jade Biosciences, Inc. Filed Acc 0001415889-23-010965

CHIEF SCIENTIFIC OFFICER sold 2,250 shares at an average $17.30 ($38,915)

  • CHIEF SCIENTIFIC OFFICER acquired 2,250 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

NIVEN RALPH · CHIEF SCIENTIFIC OFFICER

Table I: Non-derivative

4 lines
Date Transaction Shares Price Value Owned after D/I
2023-07-05 Exercise or conversion : show line 1 in the form 10b5-1 +650 $1.74 $1,131 2,259 D
2023-07-05 Exercise or conversion : show line 2 in the form 10b5-1 +1,600 $2.14 $3,424 3,859 D
2023-07-05 Sale : show line 3 in the form 10b5-1 −2,031 $17.23 $35,002 1,828 D
2023-07-05 Sale : show line 4 in the form 10b5-1 −219 $17.87 $3,913 1,609 D
Open-market sales · 2,250 sh · avg $17.30 · $38,915

Table II: Derivative

5 lines
Date Transaction Shares Owned after D/I
2023-07-05 Exercise or conversion : show line 5 in the form 10b5-1 Stock Option (Right to Buy) −450 18,708 D
2023-07-05 Exercise or conversion : show line 6 in the form 10b5-1 Stock Option (Right to Buy) −200 12,088 D
2023-07-05 Exercise or conversion : show line 7 in the form 10b5-1 Stock Option (Right to Buy) −200 13,894 D
2023-07-05 Exercise or conversion : show line 8 in the form 10b5-1 Stock Option (Right to Buy) −650 42,108 D
2023-07-05 Exercise or conversion : show line 9 in the form 10b5-1 Stock Option (Right to Buy) −750 50,732 D
Loading xslF345X04/form4-07072023_060701.xml…